July 24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (PCAC)
Pharmacy Compounding Advisory Committee · July 24, 2026
FDA Pharmacy Compounding Advisory Committee (PCAC) Day 2 (July 24, 2026): the committee heard presentations and public comment on several peptide bulk drug substance nominations (imideltide/DSIP; epitalon; CMAX; semax-related items), questioned FDA staff about characterization, safety, and evidence, and voted on whether each substance should be placed on the section 503A bulks list.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.